EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Axial Spondyloarthritis Treatment Recommendations in 2024: Where Are We Now?

Sherry Rohekar

Canadian Rheumatology Today · 2024

DOI: 10.58931/crt.2024.1252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Rheumatology Today, 2024. Verfasst von Sherry Rohekar. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As 2024 continues to evolve, so do treatment recommendations for the management of spondyloarthritis (SpA), including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). From a Canadian perspective, we eagerly await the publication of the Canadian Rheumatology Association (CRA)/Spondyloarthritis Research Consortium of Canada (SPARCC) Living Treatment Recommendations for the Management of Axial Spondyloarthritis (axSpA), currently in press. Until these recommendations for axSpA treatment with a Canadian perspective arrive – where are we now?

Zitieren

APA

Rohekar, S. (2024). Axial Spondyloarthritis Treatment Recommendations in 2024: Where Are We Now?. Canadian Rheumatology Today. https://doi.org/10.58931/crt.2024.1252

Vancouver

Rohekar S. Axial Spondyloarthritis Treatment Recommendations in 2024: Where Are We Now?. Canadian Rheumatology Today. 2024. doi:10.58931/crt.2024.1252

BibTeX
@article{Rohekar2024,
  author = {Rohekar, Sherry},
  title = {Axial Spondyloarthritis Treatment Recommendations in 2024: Where Are We Now?},
  journal = {Canadian Rheumatology Today},
  year = {2024},
  doi = {10.58931/crt.2024.1252}
}
Kostenlos starten →